Triple combinations in chronic obstructive pulmonary disease - Is three better than two?

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 17, 2014, Pages 2475-2478

  Cazzola, Mario ^a   Matera, Maria Gabriella ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Bronchodilators; Chronic obstructive pulmonary disease; Combination therapy; Inhaled corticosteroids; Triple therapy

Indexed keywords

BECLOMETASONE; BECLOMETHASONE PLUS FORMOTEROL PLUS GLYCOPYRRONIUM; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; BUDESONIDE PLUS FORMOTEROL FUMARATE PLUS GLYCOPYRRONIUM; CICLESONIDE; CICLESONIDE PLUS FORMOTEROL FUMARATE PLUS TIOTROPIUM; CORTICOSTEROID; FLUTICASONE FUROATE PLUS UMECLIDINIUM PLUS VILANTEROL; FLUTICASONE FUROATE PLUS VILANTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; FORMOTEROL FUMARATE; GLYCOPYRRONIUM BROMIDE; INDACATEROL; MUSCARINIC RECEPTOR BLOCKING AGENT; SALMETEROL; TIOTROPIUM BROMIDE; UMECLIDINIUM; UMECLIDINIUM PLUS VILANTEROL; UNCLASSIFIED DRUG; VILANTEROL; BRONCHODILATING AGENT; GLUCOCORTICOID;

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMBINATION CHEMOTHERAPY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; FORCED EXPIRATORY VOLUME; HEALTH CARE PERSONNEL; HUMAN; LUNG FUNCTION; METERED DOSE INHALER; PRACTICE GUIDELINE; PRESCRIPTION; CLINICAL TRIAL (TOPIC); DRUG COMBINATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; BRONCHODILATOR AGENTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; MUSCARINIC ANTAGONISTS; PRACTICE GUIDELINES AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84910083629     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.972367     Document Type: Article

References (26)

1. National Institute for Health and Clinical Excellence. NICE clinical guideline 101. Available from: http://www.nice.org.uk/nicemedia/live/13029/49397/49397.pdf [Accessed 20 September 2014]
2. GOLD strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Available from: http://www.goldcopd.org/uploads/users/files/GOLD-Report2014-Feb07.pdf [Accessed 20 September 2014]
3. James GD, Donaldson GC, Wedzicha JA, Nazareth I. Trends in management and outcomes of COPD patients in primary care, 2000-2009: a retrospective cohort study. NPJ Prim Care Respir Med 2014;24:14015
4. Corrado A, Rossi A. How far is real life from COPD therapy guidelines? An Italian observational study. Respir Med 2012;106:989-97
5. Wurst KE, Punekar YS, Shukla A. Treatment evolution after COPD diagnosis in the UK primary care setting. PLoS One 2014;9:e105296
6. Cazzola M, Matera MG. Bronchodilators: current and future. Clin Chest Med 2014;35:191-201
7. Cazzola M, Segreti A, Rogliani P. Comparative effectiveness of drugs for chronic obstructive pulmonary disease. Drugs Today (Barc) 2012;48:785-94
8. Karner C, Cates CJ. Combination inhaled steroid and long-acting beta2-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011;3
9. Gaebel K, McIvor RA, Xie F, et al. Triple therapy for the management of COPD: a review. COPD 2011;8:206-43
10. Rodrigo GJ, Plaza V, Castro-Rodríguez JA. Comparison of three combined pharmacological approaches with tiotropium monotherapy in stable moderate to severe COPD: a systematic review. Pulm Pharmacol Ther 2012;25:40-7
11. Liu Y, Shi H, Sun X, et al. Benefits of adding fluticasone propionate/salmeterol to tiotropium in COPD: a meta-analysis. Eur J Intern Med 2014;25:491-5
12. Manoharan A, Short PM, Anderson WJ, Lipworth BJ. Impact of long-acting bronchodilators and exposure to inhaled corticosteroids on mortality in COPD: a real-life retrospective cohort study. Lung 2014;92:649-52
13. Hoshino M, Ohtawa J. Effects of tiotropium and salmeterol/fluticasone propionate on airway wall thickness in chronic obstructive pulmonary disease. Respiration 2013;86:280-7
14. Kraemer M, Ellis A, Baldwin M, et al. Dual bronchodilation with indacaterol and tiotropium in combination versus triple therapy, fixed-dose combinations, and monotherapy in COPD - a network meta-analysis of FEV1 [abstract]. Value Health 2012;15:A560
15. Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014;371:1285-94
16. Vincken W, Auman J, Goyal P, Altman P. Free triple combination of glycopyrronium, indacaterol and ICS improves lung function and dyspnoea versus free double combination of indacaterol and ICS in patients with COPD: a post-hoc analysis from the GLOW6 study [abstract]. Eur Respir J 2014;44:P2410
17. Reisner C, Fernandez C, Darken P, et al. Pearl's PT010 triple combination provides comparable budesonide exposure to symbicort and comparable glycopyrronium and formoterol exposure to PT003 [abstract]. Eur Respir J 2014;44:1891
18. Cazzola M, Rogliani P, Novelli L, Matera MG. Inhaled corticosteroids for chronic obstructive pulmonary disease. Expert Opin Pharmacother 2013;14:2489-99
19. Pasqua F, Biscione G, Crigna G, et al. Combining triple therapy and pulmonary rehabilitation in patients with advanced COPD: a pilot study. Respir Med 2010;104:412-17
20. Bateman ED, Mahler DA, Vogelmeier CF, et al. Recent advances in COPD disease management with fixed-dose long-acting combination therapies. Expert Rev Respir Med 2014;8:357-79
21. Reilly JJ. Stepping down therapy in COPD. N, Engl J, Med. 2014;371:1340-1
22. Tashkin DP. Roflumilast: the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD. Expert Opin Pharmacother 2014;15:85-96
23. Giembycz MA, Newton R. How phosphodiesterase 4 inhibitors work in patients with chronic obstructive pulmonary disease of the severe, bronchitic, frequent exacerbator phenotype. Clin Chest Med 2014;35:203-17
24. Calverley PM, Martinez FJ, Fabbri LM, et al. Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol. Int J Chron Obstruct Pulmon Dis 2012;7:375-82
25. Page C, Cazzola M. Bifunctional drugs for the treatment of asthma and chronic obstructive pulmonary disease. Eur Respir J 2014;44:475-82
26. Calzetta L, Page CP, Spina D, et al. Effect of the mixed phosphodiesterase 3/4 inhibitor RPL554 on human isolated bronchial smooth muscle tone. J Pharmacol Exp Ther 2013;346:414-23